Clinical Trials
28 trialsNCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT06457997 2026-01-29
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Terminated
NCT04106492 2025-11-14
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
Phase 1/2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT06376253 2025-08-07
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Novartis
Phase 1 Terminated
NCT05274451 2025-07-01
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase 1 Terminated
NCT05891197 2025-07-01
START
Lyell Immunopharma, Inc.
Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04875806 2025-04-22
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Terminated
NCT04209465 2025-04-17
MasterKey-01
Black Diamond Therapeutics, Inc.
Phase 1 Terminated
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT03127098 2024-08-06
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT05363605 2023-12-19
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT02189174 2021-12-03
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02900248 2019-04-02
N1
CureOne
Terminated
NCT01891669 2019-01-09
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00539968 2015-02-05
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00689065 2013-11-01
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Phase 1 Terminated
NCT01010334 2013-08-14
Comparison of Standard of Care or Treatment on Protocol
New Mexico Cancer Research Alliance
Phase NA Terminated
NCT01383408 2013-05-07
Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection
Schillerhoehe Hospital
Phase 2 Terminated
NCT00253461 2012-03-20
11C Topotecan PET Imaging
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01212887 2012-02-28
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Cancer Research UK
Phase 1 Terminated
NCT01096381 2012-02-27
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
Vanderbilt-Ingram Cancer Center
Terminated